Search:

Login | Subscribe

Home > Companies > Summit Corporation

Price	Market	Sector	Market Cap
60.50p (0.00p) 0.00%	AIM	Medicine and Biotech Research	£33.86m

Add to company folder | Print

Related Companies

CRX	3.75p	15.38%
EVC	25.75p	0.00%
FUL	2.50p	-9.09%
FUM	41.25p	0.00%
GMX	3.50p	0.00%
GWP	38.00p	0.00%
HML	0.70p	0.00%
MMG	11.50p	-6.12%
MPM	19.50p	0.00%
OMH	11.75p	2.17%
PSG	4.50p	0.00%
PLE	36.00p	0.00%
PRM	39.50p	0.00%
PRX	98.50p	0.00%
RNSM	7.75p	0.00%
RCG	63.25p	0.00%
RGT	13.00p	0.00%
SNG	44.00p	0.00%
TED	12.50p	2.04%
VOX	p

Commentary

Discovers and develops proprietary novel drugs and provides services to the pharmaceutical industry

Recent Articles

Summit	25/07/2008
Losses hit Summit	03/06/2008
VASTox	31/05/2007
Runners and riders in the medical stakes	10/04/2006
VASTox flexes its muscles	27/02/2006

Recent Announcements

Trading Statement	31/01/2008
Start of Ph II clinical trial	16/01/2008
Change of Adviser	06/12/2007
Director/PDMR Shareholding	05/11/2007
Re Agreement	30/10/2007
Interim Results	30/10/2007
Holding in Company	25/10/2007
Clinical Update	23/10/2007
Notice of Results	12/10/2007
Research Donation	02/10/2007
More

Articles from the Sector

Source BioScience plans restructure	28/08/2008
Asterand slashes interim loss	27/08/2008
ProStrakan targets USA	21/08/2008
Proximagen	18/08/2008
Chi-Med bullish despite interim losses	06/08/2008
Pharmaceuticals & biotechnology	04/08/2008
PuriCore seeks £10m	31/07/2008
Axis-Shield wins China patent	21/07/2008
Concateno – niche market, nice margins	30/06/2008
Interim growth at GW	19/06/2008
More

Financial History

Financial Year End	31/01/2004	31/01/2005	31/01/2006	31/01/2007	31/01/2008
Currency	GBP	GBP	GBP	GBP	GBP
Turnover	0.00	0.11	0.53	1.03	3.03
Operating Profit	-0.02	-0.29	-1.80	-4.38	-11.77
Pretax Profit	-0.02	-0.07	-1.22	-3.51	-11.03
Earnings After Tax	-0.02	-0.05	-1.06	-3.02	-10.12
Profit Available For Dividend	0.00	0.00	0.00	0.00	0.00
Ordinary Dividends	0.00	0.00	0.00	0.00	0.00
Retained Profit	-0.02	0.00	-1.06	0.00	0.00
Shareholders Funds	0.08	14.09	13.10	20.45	27.20
Net Current Assets	0.08	14.07	12.50	0.00	0.00
Adjusted Earnings Per Share Undiluted	0.00	0.00	0.00	-8.29	-21.25
Adj Earnings Per Share	0.00	0.00	0.00	-8.29	-21.25
Dividend Per Share	0.00	0.00	0.00	0.00	0.00

Chart

Click here for interactive charting

Company Details
Address	91 Milton Park, Abingdon, OX14 4RY
Telephone	01235 443 939
Fax	01235 443 999
Executives
Chairman	Barry Price (0.03% holding)
Chief Executive	Steven Lee (0.40% holding)
Finance Director	Darren Millington (0.01% holding)
Director	Stephen Davies (12.50% holding)
Main Shareholders
	Morstan Nominees: 9% IP2IPO: 8.1% Kay Davies: 7.8% The First Cambridge Gateway General: 6%
Advisers
Nominated Adviser	Panmure Gordon
Nominated Broker	Panmure Gordon
Solicitors	Pinsent Masons
Auditors	BDO Stoy Hayward
Registrar	Capita Registrars

Commentary
Discovers and develops proprietary novel drugs and provides services to the pharmaceutical industry
Company Data
Code	SUMM
Sedol	GB00B02T3K
Shares In Issue	55.968 m
Indices
Entry on AIM	14/10/2004
Interim Results	Oct
Final Results	Jun
Year End	Jan
Accounts Due	n/a
Int div payment	n/a
Fin div payment	n/a
Int net div per share	nil
Fin net div per share	nil
Probable CGT relief	Yes